MultiCell Technologies, Inc. (OTCMKTS:MCET) Enjoys New Growth
MultiCell Technologies, Inc. (OTCMKTS:MCET) is in the sweet spot of most pharmaceutical companies- boosted by enough recent developments, and still interesting enough to investors to support a period of significant price growth. On Monday, MCET opened the week strongly, with a net daily gain of 40% to $0.0021, on dollar volumes above $1.31 million. MCET still remains a double-zero stock, but one that may move under the rules for promising biotech companies. 
The latest PR messages from the company outline its efforts to patent its RNA treatments through the US and international protection systems. Still, MCET is perceived as a technical trading opportunity, due to the rather low price and the relatively robust volumes. MCET is for now not boosted by an email promotion. The rise from triple-zero positions at the beginning of March is also not so unusual on the OTC markets, especially given that MCET remains a pure-play pharmaceutical company, with no claims to touching the medical marijuana market. 
To the benefit of MCET, the company has a strange stock structure, with 3.15 billion shares outstanding- but a miniature free float of 600,000 shares. Investors’ forums see this as an opportunity to create a short-term squeeze and lift MCET to a price of a few cents. Unfortunately, this also means holdings of shares waiting in the sidelines, to be sold off at a moment when the price starts to look right.
The levels of MCET held on as it announced its latest round of financial results at the end of February. The ongoing research and development should rely on the following resources:
- $146,205 cash
- $179,085 assets
- $1.27 million total current liabilities
- $49,318 annual revenues
- $1.36 million net loss
All of this looks like the traces of a prolonged research process, which is starting to overwhelm MCET, and the proposed treatments, though modern, are still very far from generating income.
In this, MCET resembles the once-upon rise of Advanced Cell Technology, Inc. (OTCMKTS:ACTC). The company, relying on stem cell promises, had dramatic days of gains, but so far remains locked in a relatively low price, unable to break through above 10 cents after spending months between $0.05 and $0.07. ACTC had a recent run, but renewed its sideways drift.
Not even the giant Titan Pharmaceuticals, Inc. (OTCBB:TTNP) could manage to break out of the bad news cycle. TTNP is stuck near the $0.70 range, despite the expectations that such a promising company should easily vault the dollar levels. TTNP is also known for crashing by up to 75% on days of bad news.
If you like MCET for the possibility of significant percentage gains, note that those happen only on separate days. Do not rely too much that MCET will take care to boost the stock price with timely PR, and generally be aware of the risks of very underpriced stocks.
